Shield Therapeutics (LON:STX) Sets New 52-Week Low – Time to Sell?

Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price reached a new 52-week low on Tuesday. The company traded as low as GBX 2.92 and last traded at GBX 3.05, with a volume of 1,495,080 shares changing hands. The stock had previously closed at GBX 3.

Shield Therapeutics Stock Performance

The business’s 50-day moving average price is GBX 4.84 and its 200-day moving average price is GBX 6.62. The company has a current ratio of 0.75, a quick ratio of 2.16 and a debt-to-equity ratio of -146.28. The stock has a market cap of £32.76 million, a PE ratio of -3.05 and a beta of 1.77.

About Shield Therapeutics

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.

Recommended Stories

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.